Skip to content

Tesamorelin

Also called TH9507

GHRH analog — binds pituitary GHRH receptors to drive a natural pulse of your own growth hormone, preferentially mobilizing visceral fat.

  • TypePeptide
  • FormInjectable
  • Researched forGH & Growth
Tesamorelin by AminoWell USA
Photo: AminoWell USA

Where to get Tesamorelin

AminoWell USA
Injectable
Code CAMERON

Create a free account (21+), then use code CAMERON. Sold as the form named. Approved uses are on its label; the research here goes beyond them.

Shop injectable at AminoWell USA

The short version

  • Why people research itVisceral (belly) fat reduction, improved body composition and lipid profile.
  • What the evidence isThe strongest human evidence of any growth-hormone secretagogue here.
  • What to watchNumb or tingling hands while using Tesamorelin.

How Tesamorelin works

Tesamorelin is the only compound in this class with an FDA approval, and the approval is for one specific fat depot in one specific population. Its label states the indication in as many words: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, and explicitly not for general weight management Egrifta WR label 2025.

The receptor, and why it is the right one. The label describes tesamorelin as a growth hormone-releasing factor analog that binds and stimulates human GRF receptors, causing the pituitary to release endogenous growth hormone Egrifta WR label 2025. The GHRH receptor is a class B GPCR on the somatotroph coupled to Gs: cAMP, protein kinase A, and transcription of the growth hormone gene together with acute release.

  • Injectable

On the goal map: Hepatic fat & fatty liver (Metabolic health & insulin sensitivity)

Research on Tesamorelin5 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Evidence on file: FDA-approved (visceral/HIV-lipo); human trials.

Human clinical evidence

  • The strongest human evidence of any growth-hormone secretagogue here. FDA-approved as Egrifta for HIV-associated lipodystrophy on the back of two phase-3 trials, where it cut visceral adipose tissue by roughly 15–18% over 26 weeks against placebo.

  • A separate NIH-funded trial (Stanley 2019, Lancet HIV) in people with HIV and fatty liver showed reduced liver fat. It is still the same HIV population the approval covers, so it says little about whether the effect generalizes to people without HIV.

Correlative data

  • Off-label use for visceral fat in metabolically healthy adults is common and unstudied. The approval population had a specific disease driving a specific fat distribution, and how much of the effect survives in someone without it is genuinely unknown — the mechanism should carry over, the effect size probably does not.

How the mechanism reads

  • A GHRH analog: it acts one step upstream of growth hormone, on the pituitary, so release stays pulsatile and under normal feedback control. That is the mechanistic argument for it over exogenous HGH, and it predicts the two things reliably observed — visceral fat responds first, and IGF-1 rises modestly rather than dramatically.

    Mechanistic
  • The same feedback loop predicts the downside: it cannot exceed what your pituitary can produce, so it does far less in someone whose GH axis is already failing than in someone whose axis works.

    Mechanistic

Sources

  • U.S. Food and Drug Administration. EGRIFTA WR (tesamorelin) for injection, for subcutaneous use — full prescribing information, including the IGF-1 monitoring requirement and the neoplasm warning. DailyMed, U.S. National Library of Medicine; label revised 2025
  • Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity Research and Clinical Practice 2026 · PMID 41545261
  • Yuen KCJ, et al. Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin. Frontiers in Endocrinology 2024 · PMID 39665021
  • Doycheva I, et al. Growth hormone deficiency and NAFLD: An overlooked and underrecognized link. Hepatology Communications 2022 · PMID 35765700

Tesamorelin safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Active cancer or a pituitary tumor: raising GH and IGF-1 feeds growth signaling.
  • Uncontrolled diabetes: GH-axis activation reduces insulin sensitivity.
  • Pregnancy: raising maternal GH and IGF-1 through the GHRH receptor is untested.
  • Allergy to GHRH analogs or mannitol-containing products.

What’s expected

  • Visceral belly fat falls over months, since it targets the GHRH receptor to restore GH pulses.
  • IGF-1 rises and then holds, without the pituitary tiring out over a year.
  • Joint aches or mild water retention.
  • Slightly higher fasting glucose.

Watch for

  • Numb or tingling hands while using Tesamorelin.
  • Marked swelling of ankles or face.
  • Hives or breathing trouble.
  • Much more thirst and urination.

Labs that tell you it’s working

  • IGF-1 (Insulin-like Growth Factor 1)
  • HbA1c (Hemoglobin A1c)
  • Insulin (Fasting)
  • Lipid Panel

Stabilized GHRH analog; a 52-week trial held IGF-1 up with no sign of the pituitary tiring, and glucose is the watched cost. PMID 41545261

Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON

Tesamorelin FAQ4 common questions

Is Tesamorelin approved for human use?
Tesamorelin is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
What is Tesamorelin researched for?
Visceral (belly) fat reduction, improved body composition and lipid profile.
Which labs show whether it's doing anything?
IGF-1; HbA1c; Insulin; Lipid Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for Tesamorelin: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what Tesamorelin is. Skool covers how it is run.

Free on this page

What Tesamorelin is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What Tesamorelin is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The Tesamorelin lesson: the protocol, step by step
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with codeJoin Skool